ID   TNAP3_HUMAN             Reviewed;         790 AA.
AC   P21580; B2R767; E1P588; Q2HIX9; Q5VXQ7; Q9NSR6;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   28-JAN-2026, entry version 234.
DE   RecName: Full=Tumor necrosis factor alpha-induced protein 3;
DE            Short=TNF alpha-induced protein 3;
DE            EC=2.3.2.-;
DE            EC=3.4.19.12 {ECO:0000269|PubMed:14748687, ECO:0000269|PubMed:17961127, ECO:0000269|PubMed:18164316, ECO:0000269|PubMed:23827681, ECO:0000269|PubMed:27732584};
DE   AltName: Full=OTU domain-containing protein 7C;
DE   AltName: Full=Putative DNA-binding protein A20;
DE   AltName: Full=Zinc finger protein A20;
DE   Contains:
DE     RecName: Full=A20p50;
DE   Contains:
DE     RecName: Full=A20p37;
GN   Name=TNFAIP3; Synonyms=OTUD7C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2118515; DOI=10.1016/s0021-9258(18)77165-2;
RA   Opipari A.W. Jr., Boguski M.S., Dixit V.M.;
RT   "The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type
RT   of zinc finger protein.";
RL   J. Biol. Chem. 265:14705-14708(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-125; CYS-127 AND
RP   PRO-766.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 155-790.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH TRAF1 AND TRAF2.
RX   PubMed=8692885; DOI=10.1073/pnas.93.13.6721;
RA   Song H.Y., Rothe M., Goeddel D.V.;
RT   "The tumor necrosis factor-inducible zinc finger protein A20 interacts with
RT   TRAF1/TRAF2 and inhibits NF-kappaB activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:6721-6725(1996).
RN   [9]
RP   FUNCTION, INTERACTION WITH YWHAZ AND YWHAH, AND MUTAGENESIS OF ARG-562 AND
RP   SER-565.
RX   PubMed=9299557; DOI=10.1006/bbrc.1997.7343;
RA   De Valck D., Heyninck K., Van Criekinge W., Vandenabeele P., Fiers W.,
RA   Beyaert R.;
RT   "A20 inhibits NF-kappaB activation independently of binding to 14-3-3
RT   proteins.";
RL   Biochem. Biophys. Res. Commun. 238:590-594(1997).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH TRAF2.
RX   PubMed=9882303; DOI=10.1128/jvi.73.2.1023-1035.1999;
RA   Eliopoulos A.G., Blake S.M., Floettmann J.E., Rowe M., Young L.S.;
RT   "Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK
RT   pathway through its extreme C-terminus via a mechanism involving TRADD and
RT   TRAF2.";
RL   J. Virol. 73:1023-1035(1999).
RN   [11]
RP   INTERACTION WITH TAX1BP1.
RX   PubMed=10435631; DOI=10.1038/sj.onc.1202787;
RA   de Valck D., Jin D.-Y., Heyninck K., van de Craen M., Contreras R.,
RA   Fiers W., Jeang K.-T., Beyaert R.;
RT   "The zinc finger protein A20 interacts with a novel anti-apoptotic protein
RT   which is cleaved by specific caspases.";
RL   Oncogene 18:4182-4190(1999).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11463333; DOI=10.1042/0264-6021:3570617;
RA   Evans P.C., Taylor E.R., Coadwell J., Heyninck K., Beyaert R.,
RA   Kilshaw P.J.;
RT   "Isolation and characterization of two novel A20-like proteins.";
RL   Biochem. J. 357:617-623(2001).
RN   [13]
RP   FUNCTION, MUTAGENESIS OF CYS-103, AND CATALYTIC ACTIVITY.
RX   PubMed=14748687; DOI=10.1042/bj20031377;
RA   Evans P.C., Ovaa H., Hamon M., Kilshaw P.J., Hamm S., Bauer S.,
RA   Ploegh H.L., Smith T.S.;
RT   "Zinc-finger protein A20, a regulator of inflammation and cell survival,
RT   has de-ubiquitinating activity.";
RL   Biochem. J. 378:727-734(2004).
RN   [14]
RP   FUNCTION, DOMAIN OTU, DOMAIN A20-TYPE ZINC-FINGER, AND MUTAGENESIS OF
RP   CYS-103; CYS-521; CYS-524; CYS-624 AND CYS-627.
RX   PubMed=15258597; DOI=10.1038/nature02794;
RA   Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S.,
RA   Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V., Dixit V.M.;
RT   "De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-
RT   kappaB signalling.";
RL   Nature 430:694-699(2004).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH IKBKG AND TNIP1.
RX   PubMed=16684768; DOI=10.1074/jbc.m601502200;
RA   Mauro C., Pacifico F., Lavorgna A., Mellone S., Iannetti A., Acquaviva R.,
RA   Formisano S., Vito P., Leonardi A.;
RT   "ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-
RT   kappaB.";
RL   J. Biol. Chem. 281:18482-18488(2006).
RN   [17]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=18223652; DOI=10.1038/ni1561;
RA   Coornaert B., Baens M., Heyninck K., Bekaert T., Haegman M., Staal J.,
RA   Sun L., Chen Z.J., Marynen P., Beyaert R.;
RT   "T cell antigen receptor stimulation induces MALT1 paracaspase-mediated
RT   cleavage of the NF-kappaB inhibitor A20.";
RL   Nat. Immunol. 9:263-271(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18952128; DOI=10.1016/j.bbamcr.2008.09.013;
RA   Li L., Soetandyo N., Wang Q., Ye Y.;
RT   "The zinc finger protein A20 targets TRAF2 to the lysosomes for
RT   degradation.";
RL   Biochim. Biophys. Acta 1793:346-353(2009).
RN   [20]
RP   INTERACTION WITH TAX1BP1; RNF11 AND RIPK1.
RX   PubMed=19131965; DOI=10.1038/emboj.2008.285;
RA   Shembade N., Parvatiyar K., Harhaj N.S., Harhaj E.W.;
RT   "The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB
RT   signalling.";
RL   EMBO J. 28:513-522(2009).
RN   [21]
RP   FUNCTION.
RX   PubMed=19494296; DOI=10.4049/jimmunol.0803313;
RA   Duwel M., Welteke V., Oeckinghaus A., Baens M., Kloo B., Ferch U.,
RA   Darnay B.G., Ruland J., Marynen P., Krappmann D.;
RT   "A20 negatively regulates T cell receptor signaling to NF-kappaB by
RT   cleaving Malt1 ubiquitin chains.";
RL   J. Immunol. 182:7718-7728(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-459, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE, AND SUBCELLULAR LOCATION.
RX   PubMed=20804738; DOI=10.1016/j.bbrc.2010.08.091;
RA   Malinverni C., Unterreiner A., Staal J., Demeyer A., Galaup M., Luyten M.,
RA   Beyaert R., Bornancin F.;
RT   "Cleavage by MALT1 induces cytosolic release of A20.";
RL   Biochem. Biophys. Res. Commun. 400:543-547(2010).
RN   [24]
RP   FUNCTION, INTERACTION WITH IKBKG, AND MUTAGENESIS OF 770-PHE-GLY-771;
RP   CYS-779 AND CYS-782.
RX   PubMed=22099304; DOI=10.1016/j.molcel.2011.09.015;
RA   Skaug B., Chen J., Du F., He J., Ma A., Chen Z.J.;
RT   "Direct, noncatalytic mechanism of IKK inhibition by A20.";
RL   Mol. Cell 44:559-571(2011).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [26]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23827681; DOI=10.1016/j.cell.2013.05.046;
RA   Mevissen T.E., Hospenthal M.K., Geurink P.P., Elliott P.R., Akutsu M.,
RA   Arnaudo N., Ekkebus R., Kulathu Y., Wauer T., El Oualid F., Freund S.M.,
RA   Ovaa H., Komander D.;
RT   "OTU deubiquitinases reveal mechanisms of linkage specificity and enable
RT   ubiquitin chain restriction analysis.";
RL   Cell 154:169-184(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-645, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-575, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   INVOLVEMENT IN AIFBL1.
RX   PubMed=26642243; DOI=10.1038/ng.3459;
RA   Zhou Q., Wang H., Schwartz D.M., Stoffels M., Park Y.H., Zhang Y., Yang D.,
RA   Demirkaya E., Takeuchi M., Tsai W.L., Lyons J.J., Yu X., Ouyang C.,
RA   Chen C., Chin D.T., Zaal K., Chandrasekharappa S.C., P Hanson E., Yu Z.,
RA   Mullikin J.C., Hasni S.A., Wertz I.E., Ombrello A.K., Stone D.L.,
RA   Hoffmann P., Jones A., Barham B.K., Leavis H.L., van Royen-Kerkof A.,
RA   Sibley C., Batu E.D., Guel A., Siegel R.M., Boehm M., Milner J.D., Ozen S.,
RA   Gadina M., Chae J., Laxer R.M., Kastner D.L., Aksentijevich I.;
RT   "Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency
RT   cause an early-onset autoinflammatory disease.";
RL   Nat. Genet. 48:67-73(2016).
RN   [30]
RP   STRUCTURE BY NMR OF 381-790.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the A20-type zinc finger domains from human tumor
RT   necrosis factor, alpha-induced protein 3.";
RL   Submitted (OCT-2007) to the PDB data bank.
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 1-366, CATALYTIC ACTIVITY,
RP   FUNCTION, AND MUTAGENESIS OF ASP-70; CYS-103 AND HIS-256.
RX   PubMed=17961127; DOI=10.1042/bj20071399;
RA   Komander D., Barford D.;
RT   "Structure of the A20 OTU domain and mechanistic insights into
RT   deubiquitination.";
RL   Biochem. J. 409:77-85(2008).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-370, ACTIVE SITE, CATALYTIC
RP   ACTIVITY, FUNCTION, AND MUTAGENESIS OF ASP-70; THR-97; ASP-100; CYS-103;
RP   LEU-157; TYR-159; SER-190; GLU-192; PHE-224 AND LEU-227.
RX   PubMed=18164316; DOI=10.1016/j.jmb.2007.11.092;
RA   Lin S.C., Chung J.Y., Lamothe B., Rajashankar K., Lu M., Lo Y.C., Lam A.Y.,
RA   Darnay B.G., Wu H.;
RT   "Molecular basis for the unique deubiquitinating activity of the NF-kappaB
RT   inhibitor A20.";
RL   J. Mol. Biol. 376:526-540(2008).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 592-635 IN COMPLEX WITH UBIQUITIN,
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 592-635 IN COMPLEX WITH UBIQUITIN
RP   AND UBE2D1, AND MUTAGENESIS OF TYR-614; PHE-615 AND LEU-626.
RX   PubMed=21095585; DOI=10.1016/j.molcel.2010.10.009;
RA   Bosanac I., Wertz I.E., Pan B., Yu C., Kusam S., Lam C., Phu L., Phung Q.,
RA   Maurer B., Arnott D., Kirkpatrick D.S., Dixit V.M., Hymowitz S.G.;
RT   "Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB
RT   signaling.";
RL   Mol. Cell 40:548-557(2010).
RN   [34] {ECO:0007744|PDB:5LRX}
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 1-366, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF HIS-106 AND HIS-256.
RX   PubMed=27732584; DOI=10.1038/nature19836;
RA   Mevissen T.E., Kulathu Y., Mulder M.P., Geurink P.P., Maslen S.L.,
RA   Gersch M., Elliott P.R., Burke J.E., van Tol B.D., Akutsu M., El Oualid F.,
RA   Kawasaki M., Freund S.M., Ovaa H., Komander D.;
RT   "Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase
RT   Cezanne.";
RL   Nature 538:402-405(2016).
RN   [35]
RP   VARIANT AIFBL1 TYR-243, AND CHARACTERIZATION OF VARIANT AIFBL1 TYR-243.
RX   PubMed=27175295; DOI=10.1136/rmdopen-2015-000223;
RA   Shigemura T., Kaneko N., Kobayashi N., Kobayashi K., Takeuchi Y.,
RA   Nakano N., Masumoto J., Agematsu K.;
RT   "Novel heterozygous C243Y A20/TNFAIP3 gene mutation is responsible for
RT   chronic inflammation in autosomal-dominant Behcet's disease.";
RL   RMD Open 2:E000223-E000223(2016).
CC   -!- FUNCTION: Ubiquitin-editing enzyme that contains both ubiquitin ligase
CC       and deubiquitinase activities. Involved in immune and inflammatory
CC       responses signaled by cytokines, such as TNF and IL-1 beta, or
CC       pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B
CC       activity. Essential component of a ubiquitin-editing protein complex,
CC       comprising also RNF11, ITCH and TAX1BP1, that ensures the transient
CC       nature of inflammatory signaling pathways. In cooperation with TAX1BP1
CC       promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-
CC       1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2
CC       and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In
CC       cooperation with TAX1BP1 promotes ubiquitination of UBE2N and
CC       proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation,
CC       deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes
CC       the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1
CC       proteasomal degradation and consequently termination of the TNF- or
CC       LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably
CC       acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-
CC       mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin
CC       chains on MALT1 thereby mediating disassociation of the CBM
CC       (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK
CC       activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by
CC       TNIP1 and leads to inhibition of NF-kappa-B activation. Upon
CC       stimulation by bacterial peptidoglycans, probably deubiquitinates
CC       RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic
CC       mechanism which involves polyubiquitin; polyubiquitin promotes
CC       association with IKBKG and prevents IKK MAP3K7-mediated
CC       phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able
CC       to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin
CC       chains. Inhibitor of programmed cell death. Has a role in the function
CC       of the lymphoid system. Required for LPS-induced production of pro-
CC       inflammatory cytokines and IFN beta in LPS-tolerized macrophages.
CC       {ECO:0000269|PubMed:14748687, ECO:0000269|PubMed:15258597,
CC       ECO:0000269|PubMed:16684768, ECO:0000269|PubMed:17961127,
CC       ECO:0000269|PubMed:18164316, ECO:0000269|PubMed:18952128,
CC       ECO:0000269|PubMed:19494296, ECO:0000269|PubMed:22099304,
CC       ECO:0000269|PubMed:23827681, ECO:0000269|PubMed:8692885,
CC       ECO:0000269|PubMed:9299557, ECO:0000269|PubMed:9882303}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:14748687,
CC         ECO:0000269|PubMed:17961127, ECO:0000269|PubMed:18164316,
CC         ECO:0000269|PubMed:23827681, ECO:0000269|PubMed:27732584};
CC   -!- SUBUNIT: Homodimer. Interacts with TNIP1, TAX1BP1 and TRAF2. Interacts
CC       with RNF11, ITCH and TAX1BP1 only after TNF stimulation; these
CC       interaction are transient and they are lost after 1 hour of stimulation
CC       with TNF (By similarity). Interacts with YWHAZ and YWHAH. Interacts
CC       with IKBKG; the interaction is induced by TNF stimulation and by
CC       polyubiquitin. Interacts with RIPK1. Interacts with UBE2N; the
CC       interaction requires TAX1BP1. Interacts with TRAF6; the interaction is
CC       inhibited by HTLV-1 protein Tax. {ECO:0000250,
CC       ECO:0000269|PubMed:10435631, ECO:0000269|PubMed:16684768,
CC       ECO:0000269|PubMed:19131965, ECO:0000269|PubMed:21095585,
CC       ECO:0000269|PubMed:22099304, ECO:0000269|PubMed:8692885,
CC       ECO:0000269|PubMed:9299557, ECO:0000269|PubMed:9882303}.
CC   -!- INTERACTION:
CC       P21580; Q96B67: ARRDC3; NbExp=6; IntAct=EBI-527670, EBI-2875665;
CC       P21580; Q676U5-1: ATG16L1; NbExp=3; IntAct=EBI-527670, EBI-52363471;
CC       P21580; Q14790: CASP8; NbExp=3; IntAct=EBI-527670, EBI-78060;
CC       P21580; O95995: GAS8; NbExp=3; IntAct=EBI-527670, EBI-1052570;
CC       P21580; Q9Y6K9: IKBKG; NbExp=6; IntAct=EBI-527670, EBI-81279;
CC       P21580; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-527670, EBI-739832;
CC       P21580; Q4G0R1: PIBF1; NbExp=3; IntAct=EBI-527670, EBI-14066006;
CC       P21580; P54725: RAD23A; NbExp=3; IntAct=EBI-527670, EBI-746453;
CC       P21580; Q9Y3C5: RNF11; NbExp=2; IntAct=EBI-527670, EBI-396669;
CC       P21580; Q9NWF9: RNF216; NbExp=3; IntAct=EBI-527670, EBI-723313;
CC       P21580; Q86VP1: TAX1BP1; NbExp=7; IntAct=EBI-527670, EBI-529518;
CC       P21580; P21580: TNFAIP3; NbExp=9; IntAct=EBI-527670, EBI-527670;
CC       P21580; Q15025: TNIP1; NbExp=12; IntAct=EBI-527670, EBI-357849;
CC       P21580; Q8NFZ5: TNIP2; NbExp=5; IntAct=EBI-527670, EBI-359372;
CC       P21580; Q96KP6: TNIP3; NbExp=3; IntAct=EBI-527670, EBI-2509913;
CC       P21580; Q12933: TRAF2; NbExp=10; IntAct=EBI-527670, EBI-355744;
CC       P21580; P36406: TRIM23; NbExp=6; IntAct=EBI-527670, EBI-740098;
CC       P21580; P62258: YWHAE; NbExp=3; IntAct=EBI-527670, EBI-356498;
CC       P21580; P61981: YWHAG; NbExp=4; IntAct=EBI-527670, EBI-359832;
CC       P21580; P68510: Ywhah; Xeno; NbExp=3; IntAct=EBI-527670, EBI-444641;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Lysosome.
CC   -!- SUBCELLULAR LOCATION: [A20p50]: Cytoplasm.
CC   -!- INDUCTION: By TNF.
CC   -!- DOMAIN: The A20-type zinc fingers mediate the ubiquitin ligase
CC       activity. The A20-type zinc finger 4 selectively recognizes 'Lys-63'-
CC       linked polyubiquitin. The A20-type zinc finger 4-7 are sufficient to
CC       bind polyubiquitin. {ECO:0000269|PubMed:15258597}.
CC   -!- DOMAIN: The OTU domain mediates the deubiquitinase activity.
CC       {ECO:0000269|PubMed:15258597}.
CC   -!- PTM: Proteolytically cleaved by MALT1 upon TCR stimulation; disrupts
CC       NF-kappa-B inhibitory function and results in increased IL-2
CC       production. It is proposed that only a fraction of TNFAIP3 colocalized
CC       with TCR and CBM complex is cleaved, leaving the main TNFAIP3 pool
CC       intact. {ECO:0000269|PubMed:18223652, ECO:0000269|PubMed:20804738}.
CC   -!- DISEASE: Autoinflammatory syndrome, familial, Behcet-like 1 (AIFBL1)
CC       [MIM:616744]: An autosomal dominant, autoinflammatory disorder with
CC       early onset, characterized by ulceration of mucosal surfaces,
CC       particularly in the oral and genital areas. Additional variable
CC       features include skin rash, uveitis, and polyarthritis.
CC       {ECO:0000269|PubMed:26642243, ECO:0000269|PubMed:27175295}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the peptidase C64 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/42600/TNFAIP3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M59465; AAA51550.1; -; mRNA.
DR   EMBL; AK312862; BAG35714.1; -; mRNA.
DR   EMBL; AY248754; AAO61093.1; -; Genomic_DNA.
DR   EMBL; AL357060; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47925.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW47926.1; -; Genomic_DNA.
DR   EMBL; BC113871; AAI13872.1; -; mRNA.
DR   EMBL; BC114480; AAI14481.1; -; mRNA.
DR   EMBL; AL157444; CAB75664.1; -; mRNA.
DR   CCDS; CCDS5187.1; -.
DR   PIR; A35797; A35797.
DR   RefSeq; NP_001257436.1; NM_001270507.2.
DR   RefSeq; NP_001257437.1; NM_001270508.2.
DR   RefSeq; NP_006281.1; NM_006290.4.
DR   RefSeq; XP_005267176.1; XM_005267119.1.
DR   RefSeq; XP_011534397.1; XM_011536095.2.
DR   RefSeq; XP_024302300.1; XM_024446532.2.
DR   RefSeq; XP_024302301.1; XM_024446533.2.
DR   RefSeq; XP_047275239.1; XM_047419283.1.
DR   RefSeq; XP_054212262.1; XM_054356287.1.
DR   RefSeq; XP_054212263.1; XM_054356288.1.
DR   RefSeq; XP_054212264.1; XM_054356289.1.
DR   RefSeq; XP_054212265.1; XM_054356290.1.
DR   PDB; 2EQE; NMR; -; A=597-631.
DR   PDB; 2EQF; NMR; -; A=758-790.
DR   PDB; 2EQG; NMR; -; A=381-416.
DR   PDB; 2VFJ; X-ray; 3.20 A; A/B/C/D=1-366.
DR   PDB; 3DKB; X-ray; 2.50 A; A/B/C/D/E/F=1-370.
DR   PDB; 3OJ3; X-ray; 2.50 A; I/J/K/L/M/N/O/P=592-635.
DR   PDB; 3OJ4; X-ray; 3.40 A; C/F=592-635.
DR   PDB; 3VUW; X-ray; 1.95 A; E/F/G=757-789.
DR   PDB; 3VUX; X-ray; 1.70 A; E/F/G=757-790.
DR   PDB; 3VUY; X-ray; 1.98 A; D/E/F=757-790.
DR   PDB; 3ZJD; X-ray; 1.87 A; A/B=1-366.
DR   PDB; 3ZJE; X-ray; 1.84 A; A/B=1-366.
DR   PDB; 3ZJF; X-ray; 2.20 A; A/B=1-366.
DR   PDB; 3ZJG; X-ray; 1.92 A; A/B=1-366.
DR   PDB; 5LRX; X-ray; 2.85 A; A/C/E/F=1-366.
DR   PDB; 5V3B; X-ray; 3.00 A; A/B/C/D/E/F=1-366.
DR   PDB; 5V3P; X-ray; 2.50 A; A/B/C/D/E/F=1-366.
DR   PDBsum; 2EQE; -.
DR   PDBsum; 2EQF; -.
DR   PDBsum; 2EQG; -.
DR   PDBsum; 2VFJ; -.
DR   PDBsum; 3DKB; -.
DR   PDBsum; 3OJ3; -.
DR   PDBsum; 3OJ4; -.
DR   PDBsum; 3VUW; -.
DR   PDBsum; 3VUX; -.
DR   PDBsum; 3VUY; -.
DR   PDBsum; 3ZJD; -.
DR   PDBsum; 3ZJE; -.
DR   PDBsum; 3ZJF; -.
DR   PDBsum; 3ZJG; -.
DR   PDBsum; 5LRX; -.
DR   PDBsum; 5V3B; -.
DR   PDBsum; 5V3P; -.
DR   AlphaFoldDB; P21580; -.
DR   SMR; P21580; -.
DR   BioGRID; 112983; 205.
DR   CORUM; P21580; -.
DR   DIP; DIP-33804N; -.
DR   FunCoup; P21580; 1882.
DR   IntAct; P21580; 100.
DR   MINT; P21580; -.
DR   STRING; 9606.ENSP00000481570; -.
DR   ChEMBL; CHEMBL4523200; -.
DR   MEROPS; C64.003; -.
DR   GlyCosmos; P21580; 1 site, 1 glycan.
DR   GlyGen; P21580; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P21580; -.
DR   PhosphoSitePlus; P21580; -.
DR   BioMuta; TNFAIP3; -.
DR   DMDM; 112894; -.
DR   jPOST; P21580; -.
DR   MassIVE; P21580; -.
DR   PaxDb; 9606-ENSP00000481570; -.
DR   PeptideAtlas; P21580; -.
DR   ProteomicsDB; 53879; -.
DR   Pumba; P21580; -.
DR   Antibodypedia; 1049; 522 antibodies from 47 providers.
DR   DNASU; 7128; -.
DR   Ensembl; ENST00000237289.8; ENSP00000237289.4; ENSG00000118503.19.
DR   Ensembl; ENST00000420009.6; ENSP00000401562.2; ENSG00000118503.19.
DR   Ensembl; ENST00000421450.2; ENSP00000393577.2; ENSG00000118503.19.
DR   Ensembl; ENST00000433680.2; ENSP00000409845.2; ENSG00000118503.19.
DR   Ensembl; ENST00000612899.5; ENSP00000481570.1; ENSG00000118503.19.
DR   GeneID; 7128; -.
DR   KEGG; hsa:7128; -.
DR   MANE-Select; ENST00000612899.5; ENSP00000481570.1; NM_001270508.2; NP_001257437.1.
DR   UCSC; uc003qhr.5; human.
DR   AGR; HGNC:11896; -.
DR   CIViC; 7128; 1 evidence item across 1 molecular profile.
DR   ClinPGx; PA36593; -.
DR   CTD; 7128; -.
DR   DisGeNET; 7128; -.
DR   GeneCards; TNFAIP3; -.
DR   GeneReviews; TNFAIP3; -.
DR   HGNC; HGNC:11896; TNFAIP3.
DR   HPA; ENSG00000118503; Tissue enhanced (bone marrow, urinary bladder).
DR   MalaCards; TNFAIP3; -.
DR   MIM; 191163; gene.
DR   MIM; 616744; phenotype.
DR   OpenTargets; ENSG00000118503; -.
DR   Orphanet; 674762; Early-onset autoinflammatory syndrome due to A20 haploinsufficiency.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   VEuPathDB; HostDB:ENSG00000118503; -.
DR   eggNOG; KOG4345; Eukaryota.
DR   GeneTree; ENSGT00940000158448; -.
DR   HOGENOM; CLU_019606_0_0_1; -.
DR   InParanoid; P21580; -.
DR   OMA; KCSGYCN; -.
DR   OrthoDB; 10064699at2759; -.
DR   PAN-GO; P21580; 10 GO annotations based on evolutionary models.
DR   PhylomeDB; P21580; -.
DR   PathwayCommons; P21580; -.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NF-kappa-B signaling pathway.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling.
DR   SignaLink; P21580; -.
DR   SIGNOR; P21580; -.
DR   Agora; ENSG00000118503; -.
DR   BioGRID-ORCS; 7128; 35 hits in 1222 CRISPR screens.
DR   ChiTaRS; TNFAIP3; human.
DR   EvolutionaryTrace; P21580; -.
DR   GeneWiki; TNFAIP3; -.
DR   GenomeRNAi; 7128; -.
DR   Pharos; P21580; Tbio.
DR   PRO; PR:P21580; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P21580; protein.
DR   Bgee; ENSG00000118503; Expressed in vena cava and 191 other cell types or tissues.
DR   ExpressionAtlas; P21580; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:HGNC-UCL.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0061578; F:K63-linked deubiquitinase activity; EXP:Reactome.
DR   GO; GO:0070530; F:K63-linked polyubiquitin modification-dependent protein binding; IBA:GO_Central.
DR   GO; GO:0019900; F:kinase binding; IEA:Ensembl.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0043130; F:ubiquitin binding; IPI:BHF-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0001922; P:B-1 B cell homeostasis; ISS:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISS:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:BHF-UCL.
DR   GO; GO:0007010; P:cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0072666; P:establishment of protein localization to vacuole; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0050869; P:negative regulation of B cell activation; ISS:BHF-UCL.
DR   GO; GO:0045779; P:negative regulation of bone resorption; NAS:BHF-UCL.
DR   GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IDA:UniProtKB.
DR   GO; GO:2000349; P:negative regulation of CD40 signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002677; P:negative regulation of chronic inflammatory response; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISS:BHF-UCL.
DR   GO; GO:0045824; P:negative regulation of innate immune response; ISS:UniProtKB.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; IMP:MGI.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IMP:BHF-UCL.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; ISS:BHF-UCL.
DR   GO; GO:0070429; P:negative regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway; IEA:Ensembl.
DR   GO; GO:0070433; P:negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway; IEA:Ensembl.
DR   GO; GO:0090291; P:negative regulation of osteoclast proliferation; NAS:BHF-UCL.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0034136; P:negative regulation of toll-like receptor 2 signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0034140; P:negative regulation of toll-like receptor 3 signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0034144; P:negative regulation of toll-like receptor 4 signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0034148; P:negative regulation of toll-like receptor 5 signaling pathway; IEA:Ensembl.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; ISS:BHF-UCL.
DR   GO; GO:0035872; P:nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway; TAS:Reactome.
DR   GO; GO:2000347; P:positive regulation of hepatocyte proliferation; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:BHF-UCL.
DR   GO; GO:0071947; P:protein deubiquitination involved in ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0035871; P:protein K11-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070536; P:protein K63-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0050691; P:regulation of defense response to virus by host; NAS:BHF-UCL.
DR   GO; GO:0002634; P:regulation of germinal center formation; ISS:BHF-UCL.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0061043; P:regulation of vascular wound healing; NAS:BHF-UCL.
DR   GO; GO:0002237; P:response to molecule of bacterial origin; IDA:BHF-UCL.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0072573; P:tolerance induction to lipopolysaccharide; IMP:BHF-UCL.
DR   CDD; cd22766; OTU_TNFAIP3; 1.
DR   DisProt; DP03271; -.
DR   FunFam; 4.10.240.30:FF:000001; Tumor necrosis factor alpha-induced protein 3; 1.
DR   FunFam; 4.10.240.30:FF:000003; Tumor necrosis factor alpha-induced protein 3; 1.
DR   FunFam; 1.20.5.4770:FF:000005; tumor necrosis factor alpha-induced protein 3; 1.
DR   FunFam; 3.90.70.80:FF:000011; tumor necrosis factor alpha-induced protein 3; 1.
DR   FunFam; 4.10.240.30:FF:000004; tumor necrosis factor alpha-induced protein 3 isoform X2; 1.
DR   FunFam; 4.10.240.30:FF:000002; Tumor necrosis factor, alpha-induced protein 3; 1.
DR   Gene3D; 1.20.5.4770; -; 1.
DR   Gene3D; 3.90.70.80; -; 1.
DR   Gene3D; 4.10.240.30; -; 3.
DR   InterPro; IPR051346; OTU_Deubiquitinase.
DR   InterPro; IPR003323; OTU_dom.
DR   InterPro; IPR002653; Znf_A20.
DR   PANTHER; PTHR13367:SF3; TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3; 1.
DR   PANTHER; PTHR13367; UBIQUITIN THIOESTERASE; 1.
DR   Pfam; PF02338; OTU; 1.
DR   Pfam; PF01754; zf-A20; 4.
DR   SMART; SM00259; ZnF_A20; 7.
DR   PROSITE; PS50802; OTU; 1.
DR   PROSITE; PS51036; ZF_A20; 7.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; Cytoplasm; Disease variant;
KW   DNA-binding; Hydrolase; Inflammatory response; Lysosome; Metal-binding;
KW   Multifunctional enzyme; Nucleus; Phosphoprotein; Protease;
KW   Proteomics identification; Reference proteome; Repeat; Thiol protease;
KW   Transferase; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..790
FT                   /note="Tumor necrosis factor alpha-induced protein 3"
FT                   /id="PRO_0000188791"
FT   CHAIN           2..439
FT                   /note="A20p50"
FT                   /id="PRO_0000418127"
FT   CHAIN           440..790
FT                   /note="A20p37"
FT                   /id="PRO_0000418128"
FT   DOMAIN          92..263
FT                   /note="OTU"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00139"
FT   ZN_FING         381..416
FT                   /note="A20-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   ZN_FING         472..507
FT                   /note="A20-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   ZN_FING         515..548
FT                   /note="A20-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   ZN_FING         601..636
FT                   /note="A20-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   ZN_FING         651..686
FT                   /note="A20-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   ZN_FING         710..745
FT                   /note="A20-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   ZN_FING         756..790
FT                   /note="A20-type 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   REGION          58..300
FT                   /note="TRAF-binding"
FT   REGION          157..159
FT                   /note="Interaction with ubiquitin"
FT                   /evidence="ECO:0000305"
FT   REGION          190..192
FT                   /note="Interaction with ubiquitin"
FT                   /evidence="ECO:0000305"
FT   REGION          224..227
FT                   /note="Interaction with ubiquitin"
FT                   /evidence="ECO:0000305"
FT   REGION          357..377
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          369..775
FT                   /note="Interaction with TNIP1"
FT                   /evidence="ECO:0000250"
FT   REGION          386..453
FT                   /note="Interaction with RIPK1"
FT                   /evidence="ECO:0000269|PubMed:19131965"
FT   REGION          415..434
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          447..468
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          550..583
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          605..655
FT                   /note="Required for proteasomal degradation of UBE2N and
FT                   UBE2D3, TRAF6 deubiquitination, and TAX1BP1 interaction
FT                   with UBE2N"
FT                   /evidence="ECO:0000250"
FT   REGION          606..790
FT                   /note="Sufficient for inhibitory activity of TNF-induced
FT                   NF-kappa-B activity"
FT                   /evidence="ECO:0000250"
FT   REGION          689..712
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          697..790
FT                   /note="Required for lysosomal localization and for TRAF2
FT                   lysosomal degradation"
FT   COMPBIAS        357..368
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        689..705
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        100
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        103
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   ACT_SITE        256
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:18164316"
FT   BINDING         387
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         392
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         404
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         407
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         478
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         483
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         495
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         498
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         521
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         524
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         536
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         539
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         607
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         612
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         624
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         627
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         657
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         662
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         674
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         677
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         716
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         721
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         733
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         736
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         762
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         767
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         779
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   BINDING         782
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00451"
FT   SITE            439..440
FT                   /note="Cleavage; by MALT1"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         459
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         575
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         645
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         125
FT                   /note="A -> V (in dbSNP:rs5029941)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_020447"
FT   VARIANT         127
FT                   /note="F -> C (in dbSNP:rs2230926)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_022143"
FT   VARIANT         243
FT                   /note="C -> Y (in AIFBL1; increases inflammatory cytokine
FT                   secretion; increases NF-kappaB signaling)"
FT                   /evidence="ECO:0000269|PubMed:27175295"
FT                   /id="VAR_076302"
FT   VARIANT         766
FT                   /note="A -> P (in dbSNP:rs5029957)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_029319"
FT   MUTAGEN         70
FT                   /note="D->A: Minor effect on 'Lys-48' deubiquitinase
FT                   activity. Strongly reduced 'Lys-63' deubiquitinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:17961127,
FT                   ECO:0000269|PubMed:18164316"
FT   MUTAGEN         97
FT                   /note="T->A: Minor effect on 'Lys-48' deubiquitinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   MUTAGEN         100
FT                   /note="D->A: Strongly reduced deubiquitinase activity."
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   MUTAGEN         103
FT                   /note="C->A: Loss of deubiquitinase activity."
FT                   /evidence="ECO:0000269|PubMed:14748687,
FT                   ECO:0000269|PubMed:15258597, ECO:0000269|PubMed:17961127,
FT                   ECO:0000269|PubMed:18164316"
FT   MUTAGEN         103
FT                   /note="C->S: Loss of 'Lys-63' deubiquitinating activity.
FT                   Down-regulation of TNF-induced NF-kappa-B activity less
FT                   effective."
FT                   /evidence="ECO:0000269|PubMed:14748687,
FT                   ECO:0000269|PubMed:15258597, ECO:0000269|PubMed:17961127,
FT                   ECO:0000269|PubMed:18164316"
FT   MUTAGEN         106
FT                   /note="H->A: Reduces deubiquitinase activity."
FT                   /evidence="ECO:0000269|PubMed:27732584"
FT   MUTAGEN         157
FT                   /note="L->A: Strongly reduced 'Lys-48' deubiquitinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   MUTAGEN         159
FT                   /note="Y->A: Strongly reduced 'Lys-48' deubiquitinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   MUTAGEN         190
FT                   /note="S->A: Strongly reduced 'Lys-48' deubiquitinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   MUTAGEN         192
FT                   /note="E->A: Strongly reduced 'Lys-48' deubiquitinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   MUTAGEN         224
FT                   /note="F->A: Strongly reduced 'Lys-48' deubiquitinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   MUTAGEN         227
FT                   /note="L->A: Strongly reduced 'Lys-48' deubiquitinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18164316"
FT   MUTAGEN         256
FT                   /note="H->A: Loss of deubiquitinase activity."
FT                   /evidence="ECO:0000269|PubMed:17961127,
FT                   ECO:0000269|PubMed:27732584"
FT   MUTAGEN         521
FT                   /note="C->A: No effect on ubiquitin ligase activity; when
FT                   associated with A-524."
FT                   /evidence="ECO:0000269|PubMed:15258597"
FT   MUTAGEN         524
FT                   /note="C->A: No effect on ubiquitin ligase activity; when
FT                   associated with A-521."
FT                   /evidence="ECO:0000269|PubMed:15258597"
FT   MUTAGEN         562
FT                   /note="R->A: Abolishes interactionj with YWHAZ and YWHAH;
FT                   no effect on inhibitory activity of TNF-induced NF-kappa-B
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:9299557"
FT   MUTAGEN         565
FT                   /note="S->A: Abolishes interactionj with YWHAZ and YWHAH;
FT                   no effect on inhibitory activity of TNF-induced NF-kappa-B
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:9299557"
FT   MUTAGEN         614
FT                   /note="Y->A: Impairs ubiquitination activity. Loss of
FT                   down-regulation of NF-kappa-B activity; when associated
FT                   with A-615 or R-626."
FT                   /evidence="ECO:0000269|PubMed:21095585"
FT   MUTAGEN         615
FT                   /note="F->A: Impairs ubiquitination activity. Loss of
FT                   down-regulation of NF-kappa-B activity; when associated
FT                   with A-614."
FT                   /evidence="ECO:0000269|PubMed:21095585"
FT   MUTAGEN         624
FT                   /note="C->A: Marked attenuation of ubiquitin ligase
FT                   activity and inhibition of RIPK1 degradation; when
FT                   associated with A-627."
FT                   /evidence="ECO:0000269|PubMed:15258597"
FT   MUTAGEN         626
FT                   /note="L->R: Impairs ubiquitination activity. Loss of
FT                   down-regulation of NF-kappa-B activity; when associated
FT                   with A-614."
FT                   /evidence="ECO:0000269|PubMed:21095585"
FT   MUTAGEN         627
FT                   /note="C->A: Marked attenuation of ubiquitin ligase
FT                   activity and inhibition of RIPK1 degradation; when
FT                   associated with A-624."
FT                   /evidence="ECO:0000269|PubMed:15258597"
FT   MUTAGEN         770..771
FT                   /note="FG->AA: Impairs polyubiquitin binding, abolishes
FT                   inhibition of IKK activation."
FT                   /evidence="ECO:0000269|PubMed:22099304"
FT   MUTAGEN         779
FT                   /note="C->A: Impairs polyubiquitin binding, abolishes
FT                   inhibition of IKK activation; when associated with A-782."
FT                   /evidence="ECO:0000269|PubMed:22099304"
FT   MUTAGEN         782
FT                   /note="C->A: Impairs polyubiquitin binding, abolishes
FT                   inhibition of IKK activation; when associated with A-779."
FT                   /evidence="ECO:0000269|PubMed:22099304"
FT   HELIX           10..13
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           15..27
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          33..35
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          39..42
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           43..45
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          54..56
FT                   /evidence="ECO:0007829|PDB:3ZJG"
FT   HELIX           58..68
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           71..79
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          82..84
FT                   /evidence="ECO:0007829|PDB:3ZJG"
FT   STRAND          87..89
FT                   /evidence="ECO:0007829|PDB:3DKB"
FT   STRAND          92..95
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           103..113
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           121..132
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           136..147
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           152..155
FT                   /evidence="ECO:0007829|PDB:5LRX"
FT   HELIX           164..174
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          176..178
FT                   /evidence="ECO:0007829|PDB:5LRX"
FT   STRAND          181..185
FT                   /evidence="ECO:0007829|PDB:3DKB"
FT   HELIX           193..203
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          207..211
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          213..216
FT                   /evidence="ECO:0007829|PDB:5LRX"
FT   TURN            218..220
FT                   /evidence="ECO:0007829|PDB:5LRX"
FT   STRAND          221..226
FT                   /evidence="ECO:0007829|PDB:5LRX"
FT   STRAND          231..233
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           240..242
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          248..253
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          256..263
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          267..270
FT                   /evidence="ECO:0007829|PDB:3ZJG"
FT   STRAND          272..279
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          282..285
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           293..297
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           299..306
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          309..315
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   STRAND          317..329
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           337..339
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           341..354
FT                   /evidence="ECO:0007829|PDB:3ZJE"
FT   HELIX           359..361
FT                   /evidence="ECO:0007829|PDB:3DKB"
FT   STRAND          384..386
FT                   /evidence="ECO:0007829|PDB:2EQG"
FT   TURN            398..402
FT                   /evidence="ECO:0007829|PDB:2EQG"
FT   HELIX           405..412
FT                   /evidence="ECO:0007829|PDB:2EQG"
FT   STRAND          604..606
FT                   /evidence="ECO:0007829|PDB:2EQE"
FT   STRAND          613..615
FT                   /evidence="ECO:0007829|PDB:3OJ3"
FT   HELIX           618..620
FT                   /evidence="ECO:0007829|PDB:3OJ3"
FT   HELIX           625..634
FT                   /evidence="ECO:0007829|PDB:3OJ3"
FT   HELIX           773..775
FT                   /evidence="ECO:0007829|PDB:3VUX"
FT   HELIX           780..788
FT                   /evidence="ECO:0007829|PDB:3VUX"
SQ   SEQUENCE   790 AA;  89614 MW;  320AEA97F58D4491 CRC64;
     MAEQVLPQAL YLSNMRKAVK IRERTPEDIF KPTNGIIHHF KTMHRYTLEM FRTCQFCPQF
     REIIHKALID RNIQATLESQ KKLNWCREVR KLVALKTNGD GNCLMHATSQ YMWGVQDTDL
     VLRKALFSTL KETDTRNFKF RWQLESLKSQ EFVETGLCYD TRNWNDEWDN LIKMASTDTP
     MARSGLQYNS LEEIHIFVLC NILRRPIIVI SDKMLRSLES GSNFAPLKVG GIYLPLHWPA
     QECYRYPIVL GYDSHHFVPL VTLKDSGPEI RAVPLVNRDR GRFEDLKVHF LTDPENEMKE
     KLLKEYLMVI EIPVQGWDHG TTHLINAAKL DEANLPKEIN LVDDYFELVQ HEYKKWQENS
     EQGRREGHAQ NPMEPSVPQL SLMDVKCETP NCPFFMSVNT QPLCHECSER RQKNQNKLPK
     LNSKPGPEGL PGMALGASRG EAYEPLAWNP EESTGGPHSA PPTAPSPFLF SETTAMKCRS
     PGCPFTLNVQ HNGFCERCHN ARQLHASHAP DHTRHLDPGK CQACLQDVTR TFNGICSTCF
     KRTTAEASSS LSTSLPPSCH QRSKSDPSRL VRSPSPHSCH RAGNDAPAGC LSQAARTPGD
     RTGTSKCRKA GCVYFGTPEN KGFCTLCFIE YRENKHFAAA SGKVSPTASR FQNTIPCLGR
     ECGTLGSTMF EGYCQKCFIE AQNQRFHEAK RTEEQLRSSQ RRDVPRTTQS TSRPKCARAS
     CKNILACRSE ELCMECQHPN QRMGPGAHRG EPAPEDPPKQ RCRAPACDHF GNAKCNGYCN
     ECFQFKQMYG
//
